Current Evidence and Applications of Adipose-Derived Stem Cells and Stromal Vascular Fraction in Orthopaedics, Worldwide

Robert Cucchi^*
*Correspondence: Robert Cucchi, Department of Orthopaedics and Trauma Surgery, University Hospital Bonn, Bonn, Germany, Email:

Introduction

In recent years, regenerative medicine has gained significant attention in the field of orthopaedics as a potential therapeutic approach for various musculoskeletal conditions. Among the different sources of stem cells, Adipose-Derived Stem Cells (ADSCs) and Stromal Vascular Fraction (SVF) have emerged as promising candidates due to their abundance, accessibility, and potential for differentiation into multiple cell lineages. This article provides an overview of the current evidence and applications of ADSCs and SVF in orthopaedics worldwide. Adipose tissue is a rich source of mesenchymal stem cells, known as Adipose-Derived Stem Cells (ADSCs). These cells possess self-renewal ability and can differentiate into various cell types, including bone, cartilage, muscle, and tendon. ADSCs can be obtained through a minimally invasive procedure called liposuction, which allows for the collection of adipose tissue. Stromal Vascular Fraction (SVF) is a heterogeneous cell population obtained from adipose tissue after enzymatic digestion and centrifugation. It contains a mixture of cells, including ADSCs, endothelial cells, pericytes, and immune cells, as well as growth factors and cytokines. Numerous preclinical and clinical studies have investigated the potential of ADSCs and SVF in treating various orthopaedic conditions [1].

Description

Several studies have shown that intra-articular injections of ADSCs or SVF can alleviate pain, reduce inflammation, and improve cartilage quality in patients with knee OA. ADSCs have also demonstrated the ability to regenerate damaged cartilage tissue in animal models. ADSCs have been extensively studied for bone tissue engineering applications. In both preclinical and clinical studies, ADSC-based therapies have shown promising results in enhancing bone regeneration and healing in cases of non-union fractures and large bone defects. ADSCs have shown potential for promoting tendon and ligament repair. In animal studies, ADSCs have demonstrated the ability to enhance collagen production, improve mechanical properties, and accelerate healing in injured tendons and ligaments. ADSCs have been explored for their potential in treating spinal disorders, such as disc degeneration and spinal cord injury. Preclinical studies have shown positive effects of ADSCs in promoting disc regeneration and functional recovery after spinal cord injury [2].

ADSCs have been investigated as a potential cell source for cartilage repair. Studies have shown that ADSCs can differentiate into chondrocytelike cells and promote cartilage regeneration in vitro and in animal models. Despite promising results in preclinical and early clinical studies, several challenges need to be addressed for widespread clinical translation. These challenges include the optimization of cell isolation and processing techniques, standardization of cell dosing, determination of optimal delivery methods, and ensuring long-term safety and efficacy. Clinical trials are ongoing worldwide to assess the safety and efficacy of ADSC and SVF-based therapies in various orthopaedic applications. Regulatory authorities and professional societies play a crucial role in establishing guidelines and regulations to ensure patient safety and ethical considerations in the use of these therapies [3]. The current evidence suggests that ADSCs and SVF hold great potential as regenerative therapies in orthopaedics. They have shown promising results in treating conditions such as osteoarthritis, bone defects, tendon and ligament injuries, spinal disorders, and cartilage repair. However, further research is needed to optimize the isolation, expansion, and delivery methods of these cells, as well as to establish long-term safety and efficacy profiles.

The field of regenerative medicine continues to evolve rapidly, and the use of ADSCs and SVF in orthopaedics is expected to expand in the coming years. With ongoing clinical trials and advancements in cell-based therapies, ADSCs and SVF hold promise as a viable treatment option for patients with orthopaedic conditions, offering potential benefits in tissue regeneration, pain relief, and improved functional outcomes. Orthopaedic conditions, such as musculoskeletal injuries, osteoarthritis, and cartilage defects, pose significant challenges in terms of treatment and recovery. Traditional therapeutic approaches often fall short in providing long-term relief and tissue regeneration. However, in recent years, regenerative medicine has emerged as a promising field in orthopaedics, offering innovative strategies for tissue repair and regeneration. Among the various regenerative approaches, Adipose-Derived Stem Cells (ADSCs) and Stromal Vascular Fraction (SVF) have gained substantial attention due to their abundance, accessibility, and regenerative potential. This article aims to explore the current evidence and applications of ADSCs and SVF in orthopaedics worldwide [4].

ADSCs are Mesenchymal Stem Cells (MSCs) that reside within the stromal vascular niche of adipose tissue. They possess self-renewal capabilities, multilineage differentiation potential, immunomodulatory properties, and secretion of trophic factors, making them an ideal candidate for regenerative therapies. ADSCs can be harvested through minimally invasive procedures such as liposuction, providing a readily available and abundant source of stem cells for therapeutic use. ADSCs have shown promising results in the treatment of OA, a degenerative joint disease characterized by cartilage loss. ADSCs can differentiate into chondrocytes, the cells responsible for cartilage formation, and secrete growth factors that promote cartilage regeneration. Several clinical trials have demonstrated the safety and efficacy of ADSC-based therapies in alleviating pain, improving joint function, and promoting cartilage regeneration in OA patients. ADSCs have the ability to differentiate into osteoblasts, the cells responsible for bone formation. This property makes them a valuable tool for bone regeneration in orthopaedics. ADSCs, in combination with scaffolds and growth factors, have been used in preclinical and clinical studies to enhance bone healing in fractures, non-unions, and bone defects [5].

Conclusion

Tendon and ligament injuries are common in orthopaedics and can be challenging to treat. ADSCs have shown promising results in promoting tendon and ligament regeneration. They can differentiate into tenocytes and produce extracellular matrix components, facilitating tissue repair. Moreover, ADSCs secrete various growth factors and cytokines that promote angiogenesis, reduce inflammation, and enhance tissue healing. SVF is a heterogeneous cell population obtained from adipose tissue after enzymatic digestion. It consists of various cell types, including ADSCs, endothelial cells, pericytes, fibroblasts, and immune cells. SVF retains the regenerative potential of ADSCs and also provides additional therapeutic benefits through the synergistic effects of its diverse cell population. SVF has shown promise in the treatment of cartilage defects. It contains a mixture of cells that can differentiate into chondrocytes and secrete growth factors that promote cartilage regeneration. In preclinical studies, SVF has demonstrated the ability to repair cartilage defects and improve joint function. SVF has been explored for its potential in healing soft tissue injuries, such as muscle and tendon tears. The diverse cell population within SVF can promote tissue repair and modulate the inflammatory response, facilitating the healing process. SVF exhibits anti-inflammatory properties through the secretion of various cytokines and growth factors. This feature is particularly relevant in orthopaedics, as inflammation often accompanies musculoskeletal injuries and can hinder the healing process. SVF's antiinflammatory effects can help reduce pain, swelling, and tissue damage, enhancing the recovery process.

References

1. Prakoso, Akbar Teguh, Hasan Basri, Dendy Adanta and Irsyadi Yani, et al. "The effect of tortuosity on permeability of porous scaffold."Biomedicines11 (2023): 427.

Google Scholar, Crossref, Indexed at

2. Randelli, Pietro, Filippo Randelli, Vincenza Ragone and Alessandra Menon, et al. "Regenerative medicine in rotator cuff injuries."Biomed Res Int2014 (2014).

Google Scholar, Crossref, Indexed at

3. Dohan Ehrenfest, D. M., I. Andia and M. Zumstein. "A, Zhang CQ, Pinto NR, Bielecki T. Classification of platelet concentrates (Platelet-Rich Plasma-PRP, Platelet-Rich Fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: Current consensus, clinical implications and perspectives."Muscles Ligaments Tendons J 4 (2014): 3-9.

Google Scholar, Crossref, Indexed at

4. Potapov, Ilya, Laura García‐Prat, Srikanth Ravichandran and Pura Muñoz‐Cánoves, et al. "Computational modelling of stem cell–niche interactions facilitates discovery of strategies to enhance tissue regeneration and counteract ageing." FEBS J 289 (2022): 1486-1491.

Google Scholar, Crossref, Indexed at

5. Nedunchezian, Swathi, Parikshit Banerjee, Chih-Yun Lee and Su-Shin Lee, et al. "Generating adipose stem cell-laden hyaluronic acid-based scaffolds using 3D bioprinting via the double crosslinked strategy for chondrogenesis."Mater Sci Eng C Mater Biol Appl 124 (2021): 112072.

Google Scholar, Crossref, Indexed at